PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+17.12%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$3.44B
AUM Growth
+$62.4M
(+1.8%)
Cap. Flow
-$184M
Cap. Flow
% of AUM
-5.35%
Top 10 Holdings %
Top 10 Hldgs %
43.73%
Holding
111
New
9
Increased
21
Reduced
33
Closed
19
Top Buys
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$114M |
| 2 |
Akero Therapeutics
AKRO
|
$66.2M |
| 3 |
Vir Biotechnology
VIR
|
$44.5M |
| 4 |
Medtronic
MDT
|
$41.1M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$35.2M |
Top Sells
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$153M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$137M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$80.3M |
| 4 |
Sanofi
SNY
|
$41.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$35.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
| $40.9M | 1.18% |
3,733,255
-170,000
| -4% | -$1.86M |
|
27
Protagonist Therapeutics
PTGX
$3.6B
| $40.6M | 1.18% |
1,469,761
+504,609
| +52% | +$13.9M |
|
|
SWTX
28
DELISTED
SpringWorks Therapeutics
SWTX
| $40.3M | 1.17% |
1,537,431
-541,921
| -26% | -$14.2M |
|
29
Immatics
IMTX
$644M
| $40.3M | 1.17% |
3,491,500
| – | – |
|
30
Acrivon Therapeutics
ACRV
$41.8M
| $39M | 1.13% |
3,007,858
| – | – |
|
31
Nautilus Biotechnolgy
NAUT
$82.5M
| $35.3M | 1.02% |
9,111,151
| – | – |
|
32
Crinetics Pharmaceuticals
CRNX
$3.24B
| $35.1M | 1.02% |
1,946,937
-1,607,950
| -45% | -$29M |
|
33
Disc Medicine
IRON
$2.12B
| $33M | 0.95% |
+742,838
| New | +$33M |
|
34
Roivant Sciences
ROIV
$8.91B
| $31.6M | 0.91% |
3,131,736
+439,600
| +16% | +$4.43M |
|
35
Cogent Biosciences
COGT
$1.82B
| $31.5M | 0.91% |
2,659,470
+377,146
| +17% | +$4.47M |
|
36
Harmony Biosciences
HRMY
$2.13B
| $31.4M | 0.91% |
891,370
+791,370
| +791% | +$27.8M |
|
37
BridgeBio Pharma
BBIO
$9.92B
| $30.1M | 0.87% |
1,748,933
-158,100
| -8% | -$2.72M |
|
38
Establishment Labs
ESTA
$1.11B
| $29.2M | 0.84% |
424,924
-42,933
| -9% | -$2.95M |
|
39
Verrica Pharmaceuticals
VRCA
$50.6M
| $29.1M | 0.84% |
503,898
| – | – |
|
40
Illumina
ILMN
$15.1B
| $27.2M | 0.79% |
+149,060
| New | +$27.2M |
|
41
argenx
ARGX
$45.1B
| $26.9M | 0.78% |
+69,000
| New | +$26.9M |
|
|
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $26M | 0.75% |
719,103
-855,031
| -54% | -$30.9M |
|
43
Relay Therapeutics
RLAY
$698M
| $24.4M | 0.71% |
1,943,097
| – | – |
|
44
Tarsus Pharmaceuticals
TARS
$2.41B
| $23.4M | 0.68% |
1,296,416
| – | – |
|
45
Rocket Pharmaceuticals
RCKT
$351M
| $23.2M | 0.67% |
1,168,363
+300,631
| +35% | +$5.97M |
|
46
BioMarin Pharmaceuticals
BMRN
$11.2B
| $22.8M | 0.66% |
263,207
-409,853
| -61% | -$35.5M |
|
47
Zymeworks
ZYME
$1.09B
| $20.9M | 0.6% |
2,416,232
-962,266
| -28% | -$8.31M |
|
48
Cabaletta Bio
CABA
$139M
| $19.9M | 0.58% |
1,545,000
+820,223
| +113% | +$10.6M |
|
49
Outset Medical
OM
$240M
| $19.7M | 0.57% |
60,157
-12,471
| -17% | -$4.09M |
|
50
Natera
NTRA
$23.1B
| $19.7M | 0.57% |
405,269
-301,945
| -43% | -$14.7M |
|